Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 278

1.

Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study.

Motl RW, Zivadinov R, Bergsland N, Benedict RH.

Neurodegener Dis Manag. 2016 Feb;6(1):23-9. doi: 10.2217/nmt.15.71.

PMID:
26782314
2.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Jan 18. pii: jnnp-2015-312221. doi: 10.1136/jnnp-2015-312221. [Epub ahead of print]

PMID:
26780938
3.

Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.

Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, Weinstock-Guttman B, Ramanathan M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e190. doi: 10.1212/NXI.0000000000000190. eCollection 2016 Feb.

4.

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.

Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.

5.

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S.

BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.

6.

Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.

Bergsland N, Zivadinov R, Dwyer MG, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2015 Nov 5. pii: 1352458515616204. [Epub ahead of print]

PMID:
26541795
7.

Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients.

Graziano E, Hagemeier J, Weinstock-Guttman B, Ramasamy DP, Zivadinov R.

Neuroimage Clin. 2015 Aug 1;9:110-6. doi: 10.1016/j.nicl.2015.07.013. eCollection 2015.

8.

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.

Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O.

J Neuroimaging. 2015 Nov-Dec;25(6):989-95. doi: 10.1111/jon.12293. Epub 2015 Sep 22.

PMID:
26394270
9.

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R.

Mult Scler. 2015 Sep 11. pii: 1352458515601903. [Epub ahead of print]

PMID:
26362893
10.

Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study.

Schwartz CE, Ayandeh A, Ramanathan M, Benedict R, Dwyer MG, Weinstock-Guttman B, Zivadinov R.

BMC Neurol. 2015 Aug 12;15:135. doi: 10.1186/s12883-015-0395-0.

11.

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R, Ramanathan M.

J Lipid Res. 2015 Oct;56(10):2010-8. doi: 10.1194/jlr.M060970. Epub 2015 Aug 4.

PMID:
26243484
12.

Stable neuropsychiatric status in multiple sclerosis: a 3-year study.

Roy S, Rodgers J, Drake AS, Zivadinov R, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2015 Jul 30. pii: 1352458515597570. [Epub ahead of print]

PMID:
26227003
13.

Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.

Varosanec M, Uher T, Horakova D, Hagemeier J, Bergsland N, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Dwyer MG, Havrdova E, Zivadinov R.

AJNR Am J Neuroradiol. 2015 Aug;36(8):1457-64. doi: 10.3174/ajnr.A4330. Epub 2015 Jun 25.

PMID:
26113068
14.

Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.

Alexander JS, Chervenak R, Weinstock-Guttman B, Tsunoda I, Ramanathan M, Martinez N, Omura S, Sato F, Chaitanya GV, Minagar A, McGee J, Jennings MH, Monceaux C, Becker F, Cvek U, Trutschl M, Zivadinov R.

J Neurol Sci. 2015 Aug 15;355(1-2):84-9. doi: 10.1016/j.jns.2015.05.027. Epub 2015 May 28.

15.

Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus.

Cesar B, Dwyer MG, Shucard JL, Polak P, Bergsland N, Benedict RH, Weinstock-Guttman B, Shucard DW, Zivadinov R.

AJNR Am J Neuroradiol. 2015 Oct;36(10):1874-83. doi: 10.3174/ajnr.A4354. Epub 2015 Jun 11.

PMID:
26066628
16.

Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis.

Malyavantham K, Weinstock-Guttman B, Suresh L, Zivadinov R, Shanahan T, Badgett D, Ramanathan M.

PLoS One. 2015 Jun 11;10(6):e0129503. doi: 10.1371/journal.pone.0129503. eCollection 2015.

17.

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.

Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F, Weinstock-Guttman B.

Ther Adv Neurol Disord. 2015 Mar;8(2):59-70. doi: 10.1177/1756285615572953.

18.

Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.

Modica CM, Bergsland N, Dwyer MG, Ramasamy DP, Carl E, Zivadinov R, Benedict RH.

Mult Scler. 2016 Jan;22(1):36-42. doi: 10.1177/1352458515579443. Epub 2015 Apr 28.

PMID:
25921038
19.

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Eur J Neurol. 2015 Jul;22(7):1113-23. doi: 10.1111/ene.12716. Epub 2015 Apr 22.

PMID:
25904020
20.

Dirty-Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease.

Beggs CB, Magnano C, Shepherd SJ, Belov P, Ramasamy DP, Hagemeier J, Zivadinov R.

J Neuroimaging. 2016 Jan;26(1):136-43. doi: 10.1111/jon.12249. Epub 2015 Apr 20.

PMID:
25893376
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk